Argus
•
Oct 21, 2026
PTGX: What does Argus have to say about PTGX?
Summary
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
KRYS: Raising target price to $358.00
Oct 21, 2026
•
KRYS
RCUS: Raising target price to $23.00
Oct 21, 2026
•
RCUS
KRYS: Lowering target price to $353.00
Oct 14, 2026
•
KRYS
RCUS: Lowering target price to $21.00
Oct 14, 2026
•
RCUS
US Large Cap Pick List - October 2026
Oct 09, 2026
•
APP, PFE, TSLA, SBUX, VRT, CME, MDT, MO, TJX, SYK, BSX, AMT, ORCL, LOW, NOW, XOM, ADBE, GEV, BA, MAR, BLK, CVS, AVGO, CVX, INTU, UNH, DHR, MSFT, COST, WFC, BX, WM, RTX, SPGI, DUK, SO, BKNG, GD, GE, NVDA, BAC, KO, COP, ICE, ACN, NEE, MCD, BMY, LIN, TMUS, LMT, KKR, CMCSA, NEM, PG, SCHW, APH, PEP, EQIX, PM
